Quick Answer
Prostamax is the synthetic tetrapeptide Lys-Glu-Asp-Pro (KEDP), patented by Khavinson's group in 2001 as a regulator of prostate function, with the prostate extract Prostatilen as its prototype. Peer-reviewed work is limited to chromatin studies in lymphocytes from elderly donors, a DNA melting study, computer modelling and one short rat organ culture report. The prostate disease data, including a rat prostatitis model and small patient comparisons, appear only in the patent. It is early, single-network evidence without independent replication.
Prostamax, also spelled Prostomax, is the prostate member of the Khavinson bioregulator family and the synthetic successor to Prostatilen, a polypeptide extract of animal prostate. The published literature on the tetrapeptide itself is small, around half a dozen PubMed records under the name, and most of it concerns chromosomes in blood cells rather than the prostate.
Sequence and identity
Prostamax is lysyl-glutamyl-aspartyl-proline, written Lys-Glu-Asp-Pro or KEDP (H-Lys-Glu-Asp-Pro-OH), with a molecular formula of C20H33N5O9 and a molecular weight of about 487.5 g/mol, as stated in the group's patent [1]. A 2012 paper from Tbilisi gives the sequence in its title and identifies the peptide as Prostamax in its abstract [2], and a 2022 review by the group lists it, spelled Prostomax, as KEDP [3]. The C-terminal proline is the only feature that separates the prostate peptide from Livagen (KEDA, liver) and Testagen (KEDG, testes).
Origin and tissue association
The prostate association is inherited from Prostatilen, which was studied clinically in the USSR, including in men with chronic prostatitis [4]. The 2001 patent names Prostatilen as the prototype for the new compound, describes Lys-Glu-Asp-Pro as a tetrapeptide with no structural analogues and presents it as a regulator of prostate function [1]. Unlike Livagen, whose derivation from the amino acid composition of a liver extract is stated in a published paper, we did not find a primary source explaining how this particular sequence was arrived at. The group's later papers describe KEDP as a regulator of prostate function, and the 2022 review cites the patent for it [3, 5]. The label reflects the group's own framing and has not been tested independently.
Proposed mechanism
As with the rest of the class, the proposal is that Prostamax reaches the nucleus and changes chromatin structure and gene accessibility. None of the peer-reviewed chromatin or DNA work used prostate cells. In cultured lymphocytes from people aged 75 to 88, Prostamax was reported to activate ribosomal genes and decondense chromatin, including pericentromeric heterochromatin on chromosome 1 [6]. A later study from the Tbilisi group reported more sister chromatid exchanges and more active nucleolar organiser regions, which it reads as chromatin loosening [2]. Microcalorimetry of human lymphocytes showed small shifts in chromatin melting, interpreted as partial relaxation of chromatin fibres [7], and in a DNA melting study KEDP was one of several short peptides that altered the stability of the double helix [8].
Computer modelling suggests a possible way into cells: a 2023 docking study ranked KEDP among the strongest predicted ligands of the PEPT1 peptide transporter [5]. A 2022 review noted that KEDP binds poorly to LAT1, the transporter the authors use to help explain tissue specificity for other peptides, so LAT1 does not account for its reported prostate activity [3].
What the studies actually show
| Model | What was reported | Source |
|---|---|---|
| Lymphocytes from elderly donors (in vitro) | Chromatin decondensation; ribosomal gene activation | Peer-reviewed [2, 6] |
| Human lymphocytes, microcalorimetry | Small shifts in chromatin melting | Peer-reviewed, Russian [7] |
| Purified DNA | Altered double helix stability | Peer-reviewed [8] |
| Rat prostate explants (organ culture) | Growth stimulation in young and old rats | Peer-reviewed, Russian [9] |
| Chicken embryo bladder explants | Growth stimulation | Patent only [1] |
| Rats with bacterial prostatitis; old rats | Less inflammation on histology; oxidation markers | Patent only [1] |
| Men with chronic prostatitis or prostate enlargement | Symptom and urine flow changes versus conventional treatment | Patent only, no described randomisation or blinding [1] |
The one peer-reviewed study in prostate tissue is a 2006 organ culture report in which four bioregulators, Prostamax among them, each stimulated growth of explants of their matching tissue from 3-week-old and 18-month-old rats, compared with untreated explants [9]. The abstract does not say whether Prostamax was tested on other tissues, the comparison that would actually test specificity.
The prostatitis and clinical data come from the 2001 patent [1]. It describes rats in which chronic bacterial prostatitis was induced with E. coli, with inflammation scored on histology against untreated and saline-treated controls; old rats assessed for oxidation markers; and two small comparisons in men, 35 with chronic prostatitis against 14 conventionally treated patients, and 19 with benign prostatic enlargement against 17. The patient comparisons are not described as randomised or blinded, and we found no peer-reviewed publication of any of these experiments. The patent's own test of tissue-specific activity used chicken embryo bladder explants rather than prostate tissue.
How strong is the evidence?
Thin. The peer-reviewed literature on KEDP consists of in vitro chromatin and DNA studies in non-prostate material, computer modelling and one short organ culture report. Everything that bears on prostate disease is in a patent. All of it comes from Khavinson's group and its collaborators, and much of it is in Russian or in regional journals. We found no independent replication and no registered clinical trial. The chromatin results are consistent within the Tbilisi series, but they say nothing direct about the prostate.
Prostamax is best treated as an early, single-group hypothesis. The useful experiments are obvious and undone: work in prostate epithelial or stromal cells, comparison against other tissues and control peptides to test specificity, and replication by an unaffiliated laboratory.
Where Prostamax fits
Prostamax sits within the wider family described in our overview of bioregulator peptides and the Khavinson research, which covers the origins, proposed mechanism and shared evidence problems of the class. The liver member of the same Lys-Glu-Asp series is covered in Livagen: what the research shows.
References
- Khavinson VKh, Malinin VV, Grigoriev EI. (2004). Tetrapeptide regulating prostate functions and its compositions and uses. European patent EP1353939, priority 2001, granted 25 August 2004. Patent, not peer reviewed; no PubMed record.
- Dzhokhadze TA, et al. (2012). Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro). Georgian Medical News (in Russian). PubMed 23221144
- Khavinson V, et al. (2022). Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences, 23(14). PubMed 35887081
- Tkachuk VN, Gorbachev AG, Khavinson VKh. (1991). The use of prostatilen in treating patients with chronic prostatitis. Urologiia i Nefrologiia (in Russian). PubMed 1823682
- Khavinson VK, et al. (2023). Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules, 13(3). PubMed 36979488
- Khavinson VKh, Lezhava TA, Malinin VV. (2004). Effects of short peptides on lymphocyte chromatin in senile subjects. Bulletin of Experimental Biology and Medicine, 137(1). PubMed 15085253
- Meskhi T, et al. (2004). The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ. Biofizika (in Russian). PubMed 15612551
- Solovyev AY, et al. (2015). The interaction of amino acids, peptides, and proteins with DNA. International Journal of Biological Macromolecules, 78. PubMed 25841380
- Zakutskii AN, et al. (2006). The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats. Advances in Gerontology (Uspekhi Gerontologii), 19 (in Russian). PubMed 17152728